Daprodustat: A potential game-changer in renal anemia therapy-A perspective - PubMed (original) (raw)

Daprodustat: A potential game-changer in renal anemia therapy-A perspective

Muhammad Usman Haider et al. Front Pharmacol. 2023.

Abstract

The United States FDA has approved daprodustat (DPD) as the first oral treatment option for anemia due to chronic kidney disease (CKD) in dialysis patients. Clinical trials have demonstrated DPD's efficacy and safety, showing non-inferiority to darbepoetin and suggesting reduced IV iron usage. DPD also holds potential for treating chronic kidney disease anemia in non-dialysis patients and may have benefits for patients with coexisting renal anemia and heart failure, pending further research and trials.

Keywords: HIF; anemia; chronic kidney disease; daprodustat; renal disease.

Copyright © 2023 Haider, Furqan and Mehmood.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

• Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
  Singh AK, Cizman B, Carroll K, McMurray JJV, Perkovic V, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Wiecek A, Stankus N, Strutz F, Blackorby A, Cobitz AR, Meadowcroft AM, Paul G, Ranganathan P, Sedani S, Solomon S. Singh AK, et al. JAMA Intern Med. 2022 Jun 1;182(6):592-602. doi: 10.1001/jamainternmed.2022.0605. JAMA Intern Med. 2022. PMID: 35377393 Free PMC article. Clinical Trial.
• Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
  Akizawa T, Nangaku M, Yonekawa T, Okuda N, Kawamatsu S, Onoue T, Endo Y, Hara K, Cobitz AR. Akizawa T, et al. Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1155-1165. doi: 10.2215/CJN.16011219. Epub 2020 Jul 28. Clin J Am Soc Nephrol. 2020. PMID: 32723804 Free PMC article. Clinical Trial.
• Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
  Zheng Q, Yang H, Sun L, Wei R, Fu X, Wang Y, Huang Y, Liu YN, Liu WJ. Zheng Q, et al. Pharmacol Res. 2020 Sep;159:105020. doi: 10.1016/j.phrs.2020.105020. Epub 2020 Jun 16. Pharmacol Res. 2020. PMID: 32561478 Review.
• Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
  Singh AK, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Więcek A, Blackorby A, Cizman B, Cobitz AR, Davies R, DiMino TL, Kler L, Meadowcroft AM, Taft L, Perkovic V; ASCEND-ND Study Group. Singh AK, et al. N Engl J Med. 2021 Dec 16;385(25):2313-2324. doi: 10.1056/NEJMoa2113380. Epub 2021 Nov 5. N Engl J Med. 2021. PMID: 34739196 Clinical Trial.
• Evaluating the safety and efficacy of daprodustat for anemia of chronic kidney disease: a meta-analysis of randomized clinical trials.
  Fatima K, Ahmed W, Fatimi AS, Mahmud O, Mahar MU, Ali A, Aamir SR, Nasim MT, Islam MB, Maniya MT, Azim D, Marsia S, Almas T. Fatima K, et al. Eur J Clin Pharmacol. 2022 Dec;78(12):1867-1875. doi: 10.1007/s00228-022-03395-y. Epub 2022 Oct 5. Eur J Clin Pharmacol. 2022. PMID: 36195739 Review.

Cited by

• A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023.
  Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, Michel MC. Kayki-Mutlu G, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):2949-2970. doi: 10.1007/s00210-024-03063-1. Epub 2024 Mar 26. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38530400 Free PMC article. Review.

References

1. 1. Akizawa T., Nangaku M., Yonekawa T., Okuda N., Kawamatsu S., Onoue T., et al. (2020). Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clin. J. Am. Soc. Nephrol. 15 (8), 1155–1165. 10.2215/CJN.16011219 - DOI - PMC - PubMed
2. 1. Akizawa T., Tsubakihara Y., Nangaku M., Endo Y., Nakajima H., Kohno T., et al. (2017). Effects of daprodustat, a Novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. Am. J. Nephrol. 45 (2), 127–135. 10.1159/000454818 - DOI - PubMed
3. 1. Al-Ahmad A., Rand W. M., Manjunath G., Konstam M. A., Salem D. N., Levey A. S., et al. (2001). Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol. 38 (4), 955–962. 10.1016/S0735-1097(01)01470-X - DOI - PubMed
4. 1. Anemia Studies in Chronic Kidney Disease: erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) - Full Text View - ClinicalTrials.gov (2023). Available at: https://clinicaltrials.gov/ct2/show/NCT02879305 (Accessed March 2, 2023).
5. 1. FDA Approves First Oral Treatment for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis | FDA (2023). Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-o... (Accessed March 2, 2023).

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Frontiers Media SA
  • PubMed Central